SG Americas Securities LLC Takes $173,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

SG Americas Securities LLC bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 8,710 shares of the biopharmaceutical company’s stock, valued at approximately $173,000.

Several other institutional investors also recently bought and sold shares of CPRX. Vanguard Group Inc. grew its position in shares of Catalyst Pharmaceuticals by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock valued at $127,212,000 after acquiring an additional 860,244 shares during the period. Dimensional Fund Advisors LP grew its holdings in Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after purchasing an additional 263,099 shares during the period. Pacer Advisors Inc. increased its position in shares of Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after buying an additional 2,965,310 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Catalyst Pharmaceuticals by 139.5% during the 1st quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock worth $43,445,000 after buying an additional 1,587,794 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares in the last quarter. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the transaction, the insider now owns 12,369 shares in the company, valued at $227,836.98. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 201,058 shares of company stock worth $4,018,188 in the last quarter. Company insiders own 11.00% of the company’s stock.

Analysts Set New Price Targets

CPRX has been the subject of a number of research analyst reports. Truist Financial upped their price objective on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Citigroup upped their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Finally, HC Wainwright raised their target price on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $29.50.

Catalyst Pharmaceuticals Trading Down 0.6 %

Shares of NASDAQ CPRX opened at $21.34 on Thursday. The stock has a market cap of $2.52 billion, a PE ratio of 39.52, a P/E/G ratio of 3.18 and a beta of 0.76. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.89 and a 12-month high of $21.85. The company has a 50-day moving average of $20.31 and a 200 day moving average of $17.53.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million during the quarter, compared to analyst estimates of $111.76 million. On average, sell-side analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current fiscal year.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.